Open AccessEfficacy of Evolocumab in Patients with Hypercholesterolemia
Author(s) -
Xuan Jin,
MooHyun Kim,
Young-Rak Cho,
Park Jong-Sung,
Kai Song,
Yuan Lin
Publication year - 2020
Publication title -
gosin daehakgyo uigwa daehak haksulji/kosin medical journal
Language(s) - English
Resource type - Journals
eISSN - 2586-7024
pISSN - 2005-9531
DOI - 10.7180/kmj.2020.35.2.125
Subject(s) - evolocumab , medicine , placebo , pcsk9 , apolipoprotein b , cholesterol , ldl cholesterol , statin , hyperlipidemia , endocrinology , gastroenterology , urology , lipoprotein , apolipoprotein a1 , diabetes mellitus , ldl receptor , alternative medicine , pathology
Objectives The FOURIER trial reported that inhibition of PCSK9 with evolocumab on a background of statin therapy lowered low-density lipoprotein (LDL) cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events. Here, we report data from a single center focusing on the effect of a PCSK9 inhibitor antibody on hyperlipidemia. Methods We enrolled 29 hypercholesterolemia patients who had LDL cholesterol levels ≥ 70 mg per deciliter or non-HDL cholesterol ≥ 100 mg per deciliter and were divided into two groups (placebo n = 14, evolocumab n = 15), and participated in a 72 – 96 week, randomized, double-blind, placebo-controlled trial with statin therapy. Patients were randomly assigned to receive evolocumab (140 mg every 2 weeks or 420 mg monthly) or matched placebo via subcutaneous injection. Lipid changes during follow-up were analyzed. Results The median LDL cholesterol level at baseline was 88 mg per deciliter, and the average LDL cholesterol level was 101.8 ± 20.0 mg per deciliter. At 4 weeks, the median LDL cholesterol level was 39 mg per deciliter, and the average LDL cholesterol level was 34.8 ± 51.8 mg per deciliter. Compared to placebo group, the LDL cholesterol levels were significantly reduced after treatment ( P < 0.001), as well as total cholesterol, ApoB, and ApoB/ApoA1 levels. During follow-up, no discomfort was reported at local injection sites, and no cases of abnormal liver function were observed. Conclusions Evolocumab significantly reduced LDL cholesterol levels and was well tolerated.